Inhibace

Cilazapril, the active ingredient in Inhibace, is an angiotensin-converting enzyme (ACE) inhibitor presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and to support treatment of heart failure in adult patients. It is indicated for patients requiring long‑term blood pressure control and for those with symptomatic heart failure, helping to reduce cardiovascular risk.

GNH USA supplies Inhibace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Cilazapril is an ACE inhibitor used to treat conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure and reduces the risk of stroke. - Heart failure: improves symptoms, decreases hospitalisation and supports cardiac function. - High cardiovascular risk: helps lower the incidence of major cardiovascular events in patients with hypertension or heart failure.

Cilazapril may cause a range of adverse reactions. Most are mild and reversible, but rare events can be serious.

Common Side Effects: - Cough: persistent dry cough. - Dizziness: especially on standing. - Headache. - Fatigue.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure. - Acute renal failure: sudden decline in kidney function.

Before initiating Cilazapril, several safety considerations should be reviewed. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR regularly. - Serum potassium: monitor for hyperkalaemia, especially with potassium‑sparing agents. - Pregnancy: classified as Category D; avoid use during pregnancy. - History of angioedema: contraindicated in patients with prior ACE‑inhibitor‑induced angioedema. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Cilazapril can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade increases risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia. - NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may enhance hypotensive response. - Lithium: ACE inhibition can raise lithium concentrations, risking toxicity. - Other antihypertensives (e.g., beta‑blockers): additive blood‑pressure‑lowering effect requires dose adjustment.